专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

81. 发明申请

US20170095477A1 PHARMACEUTICAL COMPOSITION COMPRISING A TRIAZOLE ANTIFUNGAL AGENT AND METHOD FOR PREPARATION THEREOF 审中-公开
公开(公告)号：US20170095477A1
公开(公告)日：2017-04-06
申请号：US15316899
申请日：2015-06-09
申请人： PHARMATHEN S.A.
发明人： EVANGELOS KARAVAS
IPC分类号： A61K31/506 , A61K9/20 , A61K9/28 , A61K9/00
CPC分类号： A61K31/506 , A61K9/0053 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/2059 , A61K9/2095 , A61K9/2846 , A61K9/2893
摘要： The present invention relates to a stable pharmaceutical formulation of solid dosage forms for oral administration comprising a therapeutically effective amount of a triazole antifungal agent or pharmaceutical acceptable salt thereof, in particular Voriconazole and an effective amount of a solubility enhancing agent. It also relates to a process for the preparation thereof.

82. 发明申请

US20170094991A1 INFANT FORMULA TABLETS 有权
公开(公告)号：US20170094991A1
公开(公告)日：2017-04-06
申请号：US14864955
申请日：2015-09-25
申请人： Mead Johnson Nutrition Company
发明人： Dattatreya Banavara , Juan M. Gonzalez
IPC分类号： A23C9/12
CPC分类号： A23L2/52 , A23L2/395 , A23L29/04 , A23L29/045 , A23L29/262 , A23L29/269 , A23L33/115 , A23L33/12 , A23L33/135 , A23L33/17 , A23L33/21 , A23L33/26 , A23L33/40 , A23P10/28 , A23V2002/00 , A61K9/2095
摘要： A nutritional compositions in a compressed solid form comprising about 5 to about 35% by weight of protein, about 5 to about 50% by weight percent of fat, and about 40 to about 70% by weight percent of carbohydrate, wherein the compressed solid form is readily dissolvable in water and has a moisture level of 4 to 17%. The nutritional composition, in certain embodiments, eliminates the need for scooping powder into narrow bottles, eliminates the need for transportation of loose powders for later reconstitution, and provides more precise serving sizes to ensure proper delivery of nutrients per feeding, while remaining readily dissolvable upon contact with a liquid. The disclosure further provides process for preparing a nutritional composition in a compressed solid form comprising cooling a powdered nutritional composition, contacting the cooled powdered nutritional composition with moisture, compressing the powdered nutritional composition under pressure, and drying the nutritional composition.

83. 发明申请

US20170087147A1 FORMULATIONS PHARMACOKINETICS OF DEUTERATED BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 审中-公开
公开(公告)号：US20170087147A1
公开(公告)日：2017-03-30
申请号：US15287406
申请日：2016-10-06
申请人： Auspex Pharmaceuticals, Inc.
发明人： Andreas Sommer , Chengzhi Zhang , John Carter , John Arthur , Margaret Bradbury , Thomas Gant , Manouchehr Shahbaz
IPC分类号： A61K31/4745 , A61K9/28 , A61K9/00 , A61K9/20
CPC分类号： A61K31/473 , A61K9/0053 , A61K9/0065 , A61K9/1676 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2072 , A61K9/2077 , A61K9/2095 , A61K9/28 , A61K9/284 , A61K9/2846 , A61K9/2866 , A61K9/288 , A61K9/4808 , A61K9/5047 , A61K9/5073 , A61K9/5078 , A61K9/5084 , A61K31/4745 , A61K45/06 , C07B2200/05 , C07D455/06
摘要： The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.

84. 发明授权

US09597291B2 Orally disintegrating tablet containing asenapine 有权
公开(公告)号：US09597291B2
公开(公告)日：2017-03-21
申请号：US14651029
申请日：2013-12-06
申请人： ALFRED E. TIEFENBACHER (GMBH & CO. KG)
发明人： Chaitanya Yogananda Gujjar , Bala Ramesha Chary Rallabandi , Pradip Shivraj Patwari , Ansgar Fitzner
IPC分类号： A61K9/20 , A61K31/404 , A61K9/00 , A61K31/407
CPC分类号： A61K31/407 , A61K9/0053 , A61K9/0056 , A61K9/2013 , A61K9/2054 , A61K9/2059 , A61K9/2077 , A61K9/2095
摘要： The present invention relates to an orally disintegrating tablet (ODT) containing asenapine maleate and to a process for preparing the ODT. In a first aspect, the present invention relates to an ODT containing asenapine maleate and low substituted hydroxypropylcellulose. In a second aspect, the present invention relates to an ODT containing crystalline asenapine maleate and the ODT is prepared using conventional tabletting techniques as direct compression and granulation. In a third aspect, the present invention relates to an ODT containing asenapine maleate and a carboxylic acid, and to the use of a carboxylic acid for enhancing storage stability of an asenapine maleate containing ODT.

85. 发明申请

US20170065553A1 ORALLY DISPERSIBLE TABLET 审中-公开
公开(公告)号：US20170065553A1
公开(公告)日：2017-03-09
申请号：US15355357
申请日：2016-11-18
申请人： Takeda Pharmaceutical Company Limited
发明人： Yutaka Tanoue , Tetsuya Matsuura , Yutaka Yamagata , Naoki Nagahara
IPC分类号： A61K31/343 , A61K9/20 , A61K9/00
CPC分类号： A61K31/343 , A61K9/0056 , A61K9/006 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/205 , A61K9/2054 , A61K9/2059 , A61K9/2063 , A61K9/2081 , A61K9/2095 , C07D307/81
摘要： The present invention provides a preparation with improved disintegration property, a preparation showing improved bioavailability of a medicament, production methods thereof and the like. A rapidly disintegrating preparation comprising granules comprising a medicament coated with a coating layer containing sugar or sugar alcohol; and a disintegrant. A production method of a rapidly disintegrating preparation including a step of producing granules comprising a medicament, a step of forming a coating layer containing sugar or sugar alcohol on the obtained granules and a step of mixing the coated granules with a disintegrant and molding the mixture.
摘要翻译：本发明提供了具有改善的崩解性的制剂，显示药物的生物利用度提高的制剂，其制备方法等。一种快速崩解制剂，其包含颗粒，其包含涂覆有含有糖或糖醇的涂层的药物; 和崩解剂。一种快速崩解制剂的制备方法，包括生产颗粒的步骤，其包括药物，在所得颗粒上形成含有糖或糖醇的包衣层的步骤，以及将包衣颗粒与崩解剂混合并模制该混合物的步骤。

86. 发明申请

US20170065524A1 Pharmaceutical Formulation Containing Gelling Agent 审中-公开
公开(公告)号：US20170065524A1
公开(公告)日：2017-03-09
申请号：US15354473
申请日：2016-11-17
申请人： Purdue Pharma L.P.
发明人： Curtis Wright , Benjamin Oshlack , Christopher Breder
IPC分类号： A61K9/20 , A61K31/485 , A61K9/28 , A61K9/00
CPC分类号： A61K9/2054 , A61J3/10 , A61K8/731 , A61K9/0002 , A61K9/0053 , A61K9/006 , A61K9/0095 , A61K9/06 , A61K9/08 , A61K9/1635 , A61K9/1641 , A61K9/1652 , A61K9/19 , A61K9/20 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/205 , A61K9/2095 , A61K9/28 , A61K9/2806 , A61K9/2813 , A61K9/284 , A61K9/2846 , A61K9/2853 , A61K9/2866 , A61K9/2893 , A61K9/48 , A61K9/4808 , A61K9/4833 , A61K9/485 , A61K9/4858 , A61K9/4866 , A61K9/4875 , A61K9/4891 , A61K9/5047 , A61K9/5078 , A61K9/5089 , A61K9/70 , A61K31/137 , A61K31/167 , A61K31/192 , A61K31/439 , A61K31/4458 , A61K31/48 , A61K31/485 , A61K45/06 , A61K47/02 , A61K47/08 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/20 , A61K47/26 , A61K47/32 , A61K47/34 , A61K47/36 , A61K47/38
摘要： Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

87. 发明申请

US20170049769A1 Abuse Deterrent Compositions and Methods of Making Same 审中-公开
标题翻译：滥用威慑组合和制作方法
公开(公告)号：US20170049769A1
公开(公告)日：2017-02-23
申请号：US15344631
申请日：2016-11-07
申请人： Acura Pharmaceuticals, Inc.
发明人： Vijai KUMAR , David DIXON , Divya TEWARI , Dilip B. WADGAONKAR
IPC分类号： A61K31/485 , A61K9/20
CPC分类号： A61K31/485 , A61K9/2009 , A61K9/2013 , A61K9/2027 , A61K9/2031 , A61K9/2059 , A61K9/2095 , A61K9/2853 , A61K9/2866 , A61K9/2893 , A61K47/32 , A61K47/34 , A61K47/38
摘要： This invention relates a therapeutic pharmaceutical composition comprising: a mixture including an opioid; polyethylene oxide in an amount of about 3 to about 40 wt % of the composition; a disintegrant; and a surfactant; wherein the disintegrant is present in an amount sufficient to cause the pharmaceutical composition to exhibit an immediate release profile.
摘要翻译：本发明涉及治疗性药物组合物，其包含：包含阿片样物质的混合物; 该聚环氧乙烷的量为组合物的约3至约40重量％; 崩解剂和表面活性剂; 其中所述崩解剂以足以使所述药物组合物呈现立即释放曲线的量存在。

88. 发明申请

US20170042820A1 Calcium Alginate Dosage Formulations, and Methods of Making and Using Thereof 审中-公开
标题翻译：海藻酸钙配方及其制作及使用方法
公开(公告)号：US20170042820A1
公开(公告)日：2017-02-16
申请号：US15235360
申请日：2016-08-12
申请人： Temple University-Of The Commonwealth System of Higher Education
发明人： David B. Lebo , Suzan Owaisat
IPC分类号： A61K9/20 , A61K31/09 , A61N1/32 , A61K47/36 , A61K9/00 , A61K31/192 , A61K31/522
CPC分类号： A61K9/205 , A61K9/0009 , A61K9/2013 , A61K9/2054 , A61K9/2095 , A61K9/282 , A61K9/286 , A61K9/2866 , A61K31/09 , A61K31/192 , A61K31/522 , A61K31/734 , A61N1/325 , A61K2300/00
摘要： An alginate and stearic acid composition is described, including methods of molding it into tablets further comprising a drug, and methods of controlling the drug release from the tablets.
摘要翻译：描述了藻酸盐和硬脂酸组合物，包括将其模制成进一步包含药物的片剂的方法，以及从片剂控制药物释放的方法。

89. 发明授权

US09566248B2 Encased-pellet tablets 有权
标题翻译：包囊丸片
公开(公告)号：US09566248B2
公开(公告)日：2017-02-14
申请号：US14484754
申请日：2014-09-12
申请人： R.P. Scherer Technologies, LLC
发明人： Harry G. Cocolas , Christin P. Hollis
IPC分类号： A61K9/20 , A61K9/50
CPC分类号： A61K9/5031 , A61K9/2031 , A61K9/2081 , A61K9/2095 , A61K9/5089
摘要： An encased-pellet tablet for an active pharmaceutical ingredient comprises an excipient layer on the outside and an inner core that is surrounded by the excipient layer. The inner core contains a plurality of coated pellets, and the coated pellets comprise pellets of the active pharmaceutical ingredient coated with a pellet coating. The excipient layer contains from about 1 wt. % to about 20 wt. % of at least one cushioning agent selected from polyhydroxyl compounds. A method for manufacturing the encased-pellet tablets involves compressing an excipient material to form a first layer; compressing a plurality of coated pellets containing an API on said first layer to form an inner core thereon and compressing additional excipient material around an exposed portion of said inner core thereby surrounding said inner core with excipient material.
摘要翻译：用于活性药物成分的包封颗粒片剂包括在外部的赋形剂层和被赋形剂层包围的内核。内芯包含多个涂覆的丸粒，并且涂覆的丸粒包含用丸粒包衣涂覆的活性药物成分的丸粒。赋形剂层含有约1wt。％至约20wt。至少一种选自多羟基化合物的缓冲剂的％。制造包裹丸剂的方法包括压缩赋形剂材料以形成第一层; 在所述第一层上压缩含有API的多个涂覆的丸粒以在其上形成内芯，并且在所述内核的暴露部分周围压缩附加的赋形剂材料，由此用赋形剂材料围绕所述内核。

90. 发明申请

US20170027875A1 FILM COATED TABLET CONTAINING CHOLINE ALFOSCERATE AND PROCESS FOR PREPARING THE SAME 有权
标题翻译：含有乙酸铝的薄膜包衣片及其制备方法
公开(公告)号：US20170027875A1
公开(公告)日：2017-02-02
申请号：US15105048
申请日：2014-12-15
申请人： DAEWOONG PHARMACEUTICAL CO., LTD.
发明人： Sang-Han PARK , Hee-Chul CHANG
IPC分类号： A61K9/28 , A61K33/12 , A61K9/20 , A61K31/661
CPC分类号： A61K9/2866 , A61K9/124 , A61K9/2095 , A61K9/282 , A61K9/284 , A61K31/661 , A61K33/12
摘要： The present invention provides a film coated tablet comprising a first film coating layer comprising hydroxypropyl methylcellulose and a second film coating layer comprising polyvinyl alcohol, on a tablet containing choline alfoscerate as an active ingredient and magnesium aluminometasilicate as an additive; and a process for preparing the same.
摘要翻译：本发明提供一种薄膜包衣片，其包含含有羟丙基甲基纤维素的第一膜包衣层和包含聚乙烯醇的第二膜包衣层，所述片剂含有作为活性成分的胆碱烯丙酯和作为添加剂的硅铝酸镁; 及其制备方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式